May 8, 2020 09:01 AM EDT
Bioregnum
R&D
Coronavirus
Opinion

More than 1,000 clin­i­cal tri­als were stopped by the pan­dem­ic — in­clud­ing dozens in PhI­II

We’ve been hear­ing plen­ty of anec­do­tal ev­i­dence of the dam­age done by the Covid-19 out­break glob­al­ly to drug R&D. But a re­searcher now …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times